Watching Fidelity National Information Services; Hearing Visa Eyeing A Full Takeover, $85-$105 Is The Range

– Betaville

byHappy Mohamed

March 1, 2023

1 minute read

– Betaville

Powell Industries Q3 EPS $(0.17) Misses $0.01 Estimate, Sales $116.00M Beat $111.57M Estimate

By Benzinga Newsdesk

Today, 6:21 PM

Powell Industries (NASDAQ:POWL) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $0.01 by 1800 percent. This is a 156.67 percent decrease over earnings of $0.30 per share from

POWL

Here’s How Much $100 Invested In ServiceNow 10 Years Ago Would Be Worth Today

By Benzinga Insights

Today, 6:21 PM

ServiceNow (NYSE:NOW) has outperformed the market over the past 10 years by 20.43% on an annualized basis producing an average annual return of 32.08%. Currently, ServiceNow has a market capitalization of $98.69 billion.

NOW

$100 Invested In Home Depot 10 Years Ago Would Be Worth This Much Today

By Benzinga Insights

Today, 6:21 PM

Home Depot (NYSE:HD) has outperformed the market over the past 10 years by 7.94% on an annualized basis producing an average annual return of 19.33%. Currently, Home Depot has a market capitalization of $315.31 billion.

HOOKIPA Highlights Preclinical Data On Combo With Co-Stimulatory 4-1BB Agonists, Adoptive T-Cell Transfer Showed T-Cell Responses, Tumor Control

By Benzinga Newsdesk

Today, 6:21 PM

Preclinical data on combination with co-stimulatory 4-1BB agonists or adoptive T cell transfer showed potent T cell responses and significant tumor control Preclinical data also expand evidence on

HOOK

Watching Fidelity National Information Services; Hearing Visa Eyeing A Full Takeover, $85-$105 Is The Range

Related Posts

Powell Industries Q3 EPS $(0.17) Misses $0.01 Estimate, Sales $116.00M Beat $111.57M Estimate

Here’s How Much $100 Invested In ServiceNow 10 Years Ago Would Be Worth Today

$100 Invested In Home Depot 10 Years Ago Would Be Worth This Much Today

HOOKIPA Highlights Preclinical Data On Combo With Co-Stimulatory 4-1BB Agonists, Adoptive T-Cell Transfer Showed T-Cell Responses, Tumor Control